# TRL for biotech products: what each level looks like from assay to market

URL: https://zernyxhub.com/blog/trl-for-biotech
Author: Dr. Abhay Tharmatt, Research Scientist, R&D, Zernyx Innovations
Published: 2026-11-01
Category: Technology readiness

> TRL in biotechnology explained with BIRAC's sector scales: what TRL 1 to 9 means for diagnostics and industrial biotech, and the TRL that BIRAC schemes expect.

**Short answer:** Indian biotech TRL follows BIRAC's 2018 sector scales. For an in vitro diagnostic kit, TRL 3 means core components optimised at lab scale and TRL 8 means a manufacturing licence and commercial-scale manufacturing. For industrial biotech, TRL 7 is a pilot demonstration at 100 L or 100 kg and TRL 8 is scale-up to 1,000 L or 1,000 kg.

"Biotech" covers products that develop in very different ways. A diagnostic kit is judged on clinical samples. An enzyme made by fermentation is judged on yield and scale. A vaccine is judged on immune response and safety in trials. One generic TRL scale cannot describe all three, which is why India's main biotech funder publishes a scale for each.

This post explains how to read those scales for products outside drugs and devices, with the levels for diagnostics and industrial biotechnology set out in full, and the readiness that BIRAC schemes ask for.

## Why does biotech need sector-specific TRLs?

The original nine-level scale was written for engineered systems. Its middle levels speak of components, breadboards and relevant environments. For a biological product, the questions are different: does the assay work in real samples, does the strain keep its yield at scale, is the product stable, and what does the regulator require?

The Biotechnology Industry Research Assistance Council (BIRAC) answered this in 2018 with separate TRL documents for drugs, vaccines, biosimilars, regenerative medicine, medical devices and diagnostics, industrial biotechnology, agriculture, aquaculture and fisheries, veterinary products, and AI, big data, IoT, software and bioinformatics. Each uses broadly the same stage names: ideation, proof of principle, proof of concept demonstrated and then established, early and late stage validation, pre-commercialisation, and commercialisation with post-market studies.

**BIRAC's stage names, from idea to market**
- TRL 1: Ideation
- TRL 2: Proof of principle
- TRL 3: Proof of concept demonstrated
- TRL 4: Proof of concept established
- TRL 5-7: Early, then late stage validation
- TRL 8: Pre-commercialisation
- TRL 9: Commercialisation, post-market studies
Exactly where TRL 6 and 7 split between early and late validation varies by sector document.

Drugs and devices have their own posts: see [TRL for drug development](https://zernyxhub.com/blog/trl-drug-development) and [TRL for medical devices](https://zernyxhub.com/blog/trl-medical-devices). The rest of this post covers diagnostics and industrial biotech, where questions come up most often.

## TRL 1 to 9 for an in vitro diagnostic kit

BIRAC's [medical devices and diagnostics document](https://www.birac.nic.in/webcontent/birac_trl_doc5_medical_devices_and_diagnosis_12_09_2018.pdf) has a separate column for in vitro diagnostic kits and reagents. In short:

| TRL | What BIRAC's diagnostics column describes | Evidence a reviewer will look for |
|---|---|---|
| 1 | Need identified; basic principles observed and reported | Literature, clinical need, target analyte |
| 2 | Hypothesis formulated and protocols developed; core components (antibodies, antigens, aptamers, nanoparticles) finalised and developed or procured | Candidate components and test protocols |
| 3 | Individual core components optimised at lab scale | Optimisation data for each component |
| 4 | Optimised core components integrated into the kit or platform | A complete kit working on reference material |
| 5 | Integrated system tested in-house extensively with clinical samples | In-house sensitivity and specificity on real samples |
| 6 | Clinical study on a statistically significant number of samples at one or two centres to define sensitivity and specificity; quality assurance certification applied for or obtained | Study protocol, sample size rationale, results, QA status |
| 7 | Multi-centric trials completed at NABL accredited centres; performance evaluation report submitted to CDSCO for a commercial licence | Independent lab reports; for notified IVDs, an NIB report |
| 8 | Manufacturing licence obtained and commercial-scale manufacturing set up | Licence and batch records |
| 9 | Commercial launch of the kit or reagents | Market launch and post-market data |

The levels at TRL 6 and 7 are the ones teams most often misplace. Read them against the PDF itself when you apply, because the table layout makes the column for each product easy to confuse.

The jump that matters most is TRL 4 to TRL 5: from reference material to clinical samples. A kit that detects a spiked analyte cleanly in buffer often loses sensitivity in serum, sputum or whole blood because of matrix effects. If you have not run real samples, you are not at TRL 5, however good the buffer data looks. Our guide to [what TRL 4 means](https://zernyxhub.com/blog/trl-4-meaning) covers the stage just before this.

Regulation enters at TRL 7 and 8. Under the [Medical Devices Rules, 2017](https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/m_device/Medical%20Devices%20Rules,%202017.pdf), in vitro diagnostics are medical devices, classified by risk into classes A to D according to the [CDSCO IVD FAQ](https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/IVD/FAQs/CDSCO-IVD-FAQ-03-2022-.pdf). The forms that matter:

| Purpose | Application | Licence | Who grants it |
|---|---|---|---|
| Test licence (make small quantities for evaluation) | Form MD-12 | Form MD-13 | Central Licensing Authority |
| Manufacture, class A or B | Form MD-3 | Form MD-5 | State Licensing Authority |
| Manufacture, class C or D | Form MD-7 | Form MD-9 | Central Licensing Authority |

For import licences of class B, C and D kits, the same FAQ asks for performance evaluation reports on three independent batches. Even for a domestic kit, plan for three batches made the same way well before TRL 7.

## TRL 1 to 9 for industrial biotechnology

BIRAC's [industrial biotechnology document](https://birac.nic.in/webcontent/birac_trl_doc7_industrial_biotechnology_12_09_2018.pdf), which also covers secondary agriculture, is the most concrete of the set because it names volumes.

**Industrial biotech: the scale-up path on BIRAC's scale**
1. Flask (TRL 2-3): Principle, then concept at flask level
2. Bioreactor (TRL 4): Lab scale to bioreactor, under 100 L
3. Process (TRL 5-6): Downstream processing; stability and repeatability
4. Pilot (TRL 7): 100 L or 100 kg demonstration
5. Scale-up (TRL 8): 1,000 L or 1,000 kg
6. Market (TRL 9): All regulatory clearances obtained

In the document's own words, TRL 1 is a literature survey with the problem identified and a hypothesis defined; TRL 2 is basic principles observed from plate or flask studies; TRL 3 is the concept proven at lab-scale flask level; TRL 4 moves from lab scale to bioreactor level at less than 100 L; TRL 5 is process development including downstream processing; TRL 6 is stability of the product and repeatability of the process; TRL 7 is a pilot-scale demonstration at 100 L or 100 kg; TRL 8 is scale-up to 1,000 L or 1,000 kg; and TRL 9 is obtaining all regulatory clearances for market entry.

Here is how that reads for one product. Take an enzyme for textile processing. Activity in shake flasks is TRL 3. The same strain in a 20 L fermenter with a defined medium is TRL 4. Adding recovery and purification, so the team has a product it can actually ship, is TRL 5. Showing that three runs give the same titre and the enzyme holds its activity in storage is TRL 6. A 100 L pilot run is TRL 7.

In fermentation projects, TRL 6 is the level most often claimed too early. Downstream processing tends to be planned after the strain work is done, and repeatability is assumed from one good run. Two or three consistent batches with a stability study are what make the claim believable.

## What TRL do BIRAC schemes expect?

| Scheme | Readiness wording | Support | Source |
|---|---|---|---|
| BIG | Ideas toward proof of concept; no TRL number stated | Up to ₹50 lakh over 18 months | [BIRAC BIG page](https://birac.nic.in/big.php) |
| PACE, Contract Research Scheme | Evidence of proof of concept, minimum TRL 3 | Up to 100% of project cost, no ceiling, in milestone instalments | [Revised PACE guidelines](https://birac.nic.in/webcontent/1712299429_Revised_PACE_guidelines.pdf) |
| SBIRI | End point of the study should be TRL 6 and below | 100% grant up to ₹50 lakh; above that, ₹50 lakh plus 50% of the excess | [BIRAC SBIRI and BIPP page](https://birac.nic.in/birac_i4.php) |
| BIPP | End point should be TRL 7 or above | BIRAC share not more than 50% | Same page |

The pattern is useful. Early grants fund getting to a proof of concept. SBIRI funds work that ends at or below TRL 6. BIPP is for the late-stage validation and scale-up beyond it, with the company carrying at least half the cost. If your project ends at a 100 L pilot, BIPP's wording fits better than SBIRI's. Check the current call document for each scheme, because these pages are not dated. Our posts on [the BIG grant](https://zernyxhub.com/blog/birac-big-grant-trl) and [BIRAC PACE](https://zernyxhub.com/blog/trl-for-birac-pace) go into those two schemes.

## Common mistakes

- Using the drug scale for a diagnostic. The levels and evidence differ; use the matching sector document.
- Counting spiked samples as clinical samples. TRL 5 for a kit needs real clinical samples.
- Claiming TRL 6 after one good fermentation run. Repeatability and stability need several runs.
- Leaving regulation until TRL 8. Classify an IVD and plan its test licence while still at TRL 5 or 6.
- Writing a TRL without the evidence beside it. See [what counts as TRL evidence](https://zernyxhub.com/blog/trl-evidence).

One caution: BIRAC's sector documents date from 2018, and India's national framework, NTRAF, arrived in December 2025. Funders may move towards NTRAF wording over time, so read the TRL definitions attached to each call. To check your own level against your evidence, [TRL Pro](https://app.zernyxhub.com/trl-calculator) lets you enter your technology and get back a readiness level from TRL 1 to 9, assessed with Zernyx's own copyrighted framework (ZTRAF) across more than 60 technology domains and subdomains.

## Common questions

### Which TRL scale should an Indian biotech startup use?

Use the BIRAC sector document that matches the product. BIRAC published separate TRL definitions in 2018 for drugs, vaccines, biosimilars, regenerative medicine, medical devices and diagnostics, industrial biotechnology, agriculture, aquaculture and fisheries, veterinary products, and AI, big data, IoT and bioinformatics.

### What TRL is an industrial biotech process at pilot scale?

BIRAC's industrial biotechnology scale puts a pilot-scale demonstration at 100 L or 100 kg at TRL 7. Bioreactor work below 100 L sits at TRL 4, and scale-up to 1,000 L or 1,000 kg is TRL 8.

### What TRL does BIRAC expect for SBIRI and BIPP?

BIRAC's SBIRI page says the end point of the proposed study should be TRL 6 and below. For BIPP, the end point should be TRL 7 or above. PACE's Contract Research Scheme asks for evidence of proof of concept, minimum TRL 3.

### Where does a CDSCO licence fit on the diagnostics TRL scale?

Late. BIRAC's diagnostics column ties TRL 8 to obtaining a manufacturing licence and setting up commercial-scale manufacturing. Under the Medical Devices Rules, 2017, a test licence is applied for on Form MD-12 and granted on Form MD-13.

---

Published by Zernyx Hub. More: https://zernyxhub.com/llms.txt
